(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 February 2006 (16.02.2006)

PCT

(10) International Publication Number
WO 2006/017692 A3

(51) International Patent Classification[7]: A61K 9/00

(21) International Application Number:
PCT/US2005/027806

(22) International Filing Date: 4 August 2005 (04.08.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/599,320	6 August 2004 (06.08.2004)	US
60/604,861	27 August 2004 (27.08.2004)	US
60/655,762	24 February 2005 (24.02.2005)	US
60/687,704	6 June 2005 (06.06.2005)	US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/687,704 (CON)
Filed on 6 June 2005 (06.06.2005)

(71) Applicant *(for all designated States except US)*: **TRANSFORM PHARMACEUTICALS, INC.** [US/US]; 29 Hartwell Avenue, Lexington, MA 2421 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ALMARSSON, Örn** [IS/US]; 22 Farmington Drive, Shrewsbury, MA 01545 (US). **RATANABANANGKOON, Pasut** [TH/TH]; 55/158 Soi 29 Lad Phrao Road, Jatujak, Bangkok 10900 (TH). **REMENAR, Julius** [US/US]; 9 Eaton Road, Framingham, MA 01701 (US). **GUZMAN, Hector** [US/US]; 47 Wyman Street, Jamaica Plain, MA 02130 (US).

(74) Agent: **BURGESS, Paul**; Transform Pharmaceuticals, Inc., 29 Hartwell avenue, Lexington, MA 02421 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US (patent), UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
6 April 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL FENOFIBRATE FORMULATIONS AND RELATED METHODS OF TREATMENT

(57) Abstract: The invention provides novel omega-3 ester-based oil solutions of fenofibrate. These solutions are substantially free of any food effect, effective in small volumes, and readily bioavailable. Notably, because the solutions of the invention contain an omega-3 ester-based oil as the major ingredient, the y not only provide an antihyperlipidemic effect due to the fenofibrate active ingredient, they also provide recommended daily dosages of omega-3 oils (i.e., approximately 1 gram of omega-3 oil per day), or a portion thereof.

WO 2006/017692 A3